Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · MEDI CAPS LTD. · 9 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
MEDI CAPS LTD.
NSE: MEDICAPQ · BSE: 523144
NSE: MEDICAPQ · BSE: 523144
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
MEDI CAPS LTD.
StateQ4 FY26 filed
Last close · 9 Oct 2026₹25.50
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA— · 0.28 · —
MEDI CAPS LTD. is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 70 | 49 | 27 | 25 | 12 |
| EBITDA (ex other income) | 10 | 5 | (0) | (2) | (9) |
| margin % | 14.3 | 10.3 | (0.1) | (7.2) | (75.6) |
| Owners' profit | 10 | 2 | (2) | (1) | (3) |
| EPS, as reported (₹) | 8.08 | 1.41 | (1.80) | (0.46) | (2.44) |
| ROE % · ROCE % | 8.7 · 8.6 | 1.5 · 4.1 | (1.9) · (1.0) | (0.5) · (0.7) | (2.7) · (2.7) |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 7 | (6) | 7 | 5 | (7) |
| Capex | (3) | (1) | (0) | (0) | (1) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · MEDI CAPS LTD. · 9 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6 | 8 | 4 | 7 | 3 | 2 | 4 | 3 |
| Profit before tax | (1) | 0 | (2) | 1 | (3) | (2) | (1) | 3 |
| Net profit | (1) | 0 | (2) | 2 | (3) | (2) | (1) | 3 |
| EPS (₹) | (0.45) | 0.25 | (1.64) | 1.38 | (2.80) | (1.46) | (0.61) | 2.44 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Pharma Devision | 7 | 53.1 |
| Real Estate Devision | 2 | 12.3 |
| PHARMA DIVISION | 4 | 28.3 |
| REAL ESTATE DIVISION | 1 | 6.2 |
| Total, before eliminations | 12 | 100.0 |
Source: the filed segment block, four quarters summed.
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,23,740 | 35.0 | 5.05 | 22.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,378 | 84.7 | 14.76 | 63.8 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,56,626 | 73.9 | 8.91 | 38.9 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,626 | 24.9 | 3.77 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| LAURUS LABS LIMITED | 1,08,936 | 99.5 | 20.06 | 60.7 | 16.4 | 17.2 | 7.2 | 32.0 |
| CIPLA LTD | 1,05,836 | 31.4 | 3.07 | 16.2 | 11.2 | 14.7 | 8.0 | 19.7 |
| DR. REDDY S LABORATORIES | 99,641 | 30.8 | 2.61 | 13.4 | 10.9 | 13.0 | 12.1 | 15.0 |
| MANKIND PHARMA LIMITED | 97,439 | 47.7 | 5.88 | 26.9 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 0.3 | 3.1 | 3 of 163 | 99% |
| ROCE | (2.7) | 10.8 | 159 of 183 | 13% |
| ROE | (2.7) | 9.8 | 147 of 166 | 12% |
| Debt / Equity | 0.0 | 0.2 | 1 of 166 | 79% |
| EBITDA margin | 102.2 | 17.5 | 3 of 165 | 99% |
| Revenue growth | (50.5) | 16.3 | 154 of 161 | 4% |
| Profit growth | 77.0 | 30.9 | 46 of 158 | 71% |
| Market cap | 31 | 857 | 159 of 181 | 12% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · MEDI CAPS LTD. · 9 October 2026Page 3 of 3
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 7 Oct 2026 · Quarterly compliance certificate for dematerialization of securities | compliance | minimal | — | — |
| 25 Sept 2026 · Trading window closed from Oct 1 ahead of Q2 results | compliance | minimal | — | — |
| 23 Sept 2026 · AGM approves CMD re-appointment and new Woman Director | board shareholder meetings | medium | — | — |
| 23 Sept 2026 · Medi-Caps 43rd AGM: all 3 resolutions passed with 98.77% majority | board shareholder meetings | low | — | — |
| 22 Sept 2026 · Medi-Caps 43rd AGM held; 3 resolutions passed including CMD reappointment | board shareholder meetings | low | — | — |
| 27 Aug 2026 · Medi-Caps 43rd AGM notice published in newspapers; voting details | compliance | minimal | — | — |
| 25 Aug 2026 · Medi-Caps 43rd AGM on 22 Sept 2026; e-voting from 19 to 21 Sept | board shareholder meetings | low | — | — |
| 25 Aug 2026 · AGM notice and annual report dispatch to shareholders without email | compliance | minimal | — | — |
| 25 Aug 2026 · Medi-Caps files 43rd Annual Report for FY26 and AGM notice | board shareholder meetings | low | — | — |
| 25 Aug 2026 · 43rd AGM on 22 Sep 2026; MD reappointment and new woman director proposed | board shareholder meetings | low | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in